Subscribe
Machinery & Materials
Markets
Logistics & Cold Chain
Newsletters
Endo Pharmaceuticals
More from Endo Pharmaceuticals
Pharmaceutical
FDA Tells Endo to Pull Opioid Opana ER From Market
The FDA says the benefits of Opana Pharmaceuticals’ extended-release painkiller no longer outweigh the risk of abuse.
Pharmaceutical
FDA Says Opana’s Risks Outweigh Benefits
Opana was reformulated to deter crushing and snorting, but injecting led to a massive HIV breakout.
Pharmaceutical
Endo Recalls Erectile Dysfunction Injection
Endo Pharmaceuticals Inc. voluntarily recalls one lot of Edex due to potential lack of sterility assurance.
Pharmaceutical
1.3 Million Birth Control Pills Recalled
Endo recalls 162 lots of subpotent birth control pills manufactured by Patheon.
Home
Endo Announces Potential Short-Term Supply Constraints of Certain Analgesic Medications as a Result of Temporary Shut Down of Novartis Facility
Endo Pharmaceuticals (Nasdaq: ENDP) today announced that, as a result of a temporary shut-down of Novartis Consumer Health Inc.'s Lincoln, Neb., manufacturing facility, there will be a short-term supply constraint of OPANA ER.
